Sotera Health Co — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Sotera Health delivered Q2 2026 net revenues of $321.4M (up 9.2% YoY; 8.0% constant currency) and net income of $54M ($0.19/diluted share) vs. $8M ($0.03/share) in Q2 2025. Adjusted EBITDA grew 10.0% (8.7% constant currency) with margin expanding to 51.6%. The company raised full-year 2026 guidance: net revenues to $1.236-$1.254B (5.25-6.75% constant currency growth) and Adjusted EBITDA to $634-643M (5.75-7.25% growth). Net Leverage Ratio improved to 3.0x, achieving long-term target; company repriced term loan saving ~$3.5M annual interest; completed final PE sponsor secondary offering (no remaining sponsor ownership).
Why this rating
Strong operational beat and guidance raise signal execution, but 5-7% FY guidance growth is modest for a ~$1.2B revenue company. Leverage at target is positive; modest deleveraging and interest savings are incremental. No transformational event.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.